Harpreet Singh (file photo)

TCR-fo­cused Im­mat­ics adds an­oth­er mar­quee name to its list of part­ners: GSK

Im­mat­ics, in its fe­cund deal spree, has lured GSK, as the British drug­mak­er re­fo­cus­es its at­ten­tion to the lu­cra­tive field of on­col­o­gy.

On Thurs­day, the pri­vate­ly-held im­muno-on­col­o­gy com­pa­ny se­cured $50 mil­lion up­front in a col­lab­o­ra­tion with GSK on two T cell re­cep­tor (TCR) ther­a­peu­tics fo­cused on sol­id tu­mors. If all goes well, Im­mat­ics stands to earn more than $550 mil­lion in mile­stone pay­ments, in ad­di­tion to tiered roy­al­ties for each prod­uct.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.